Kyverna Therapeutics (KYTX) Research & Development (2023 - 2026)
Kyverna Therapeutics' Research & Development was $24.79 million in Q2 2026, down 30.8% from $35.82 million a year earlier and down 17.6% from the prior quarter.
Powered by 
Analysis
Kyverna Therapeutics (KYTX) Research & Development (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Kyverna Therapeutics' Research & Development was $115.33 million through Jun 30, 2026, down 15.2% year-over-year; for FY2025, it came in at $133.72 million, up 18.9% from FY2024.
- In earlier years, Research & Development was $112.47 million in FY2024 (+125.3%) and $49.92 million in FY2023.
- The Q2 2026 figure marks the lowest quarterly Research & Development since Q1 2024.
- Compared with a year earlier, Research & Development has declined for three straight quarters, with growth averaging 31.3% over the last eight quarters.
- The best year-over-year quarter for Research & Development over five years was Q2 2024 (growth of 162.6%); the worst was Q2 2026 (a decline of 30.8%).
- Per Business Quant data, KYTX's Research & Development in the three quarters before Q2 2026 was $30.07 million (Q1 2026), $30.01 million (Q4 2025) and $30.46 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Kyverna Therapeutics | 419.91 Mn | 419.91 Mn | - | 24.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.79 Mn |
| Mar 31, 2026 | 30.07 Mn |
| Dec 31, 2025 | 30.01 Mn |
| Sep 30, 2025 | 30.46 Mn |
| Jun 30, 2025 | 35.82 Mn |
| Mar 31, 2025 | 37.43 Mn |
| Dec 31, 2024 | 33.48 Mn |
| Sep 30, 2024 | 29.19 Mn |
| Jun 30, 2024 | 27.32 Mn |
| Mar 31, 2024 | 22.48 Mn |
| Dec 31, 2023 | 17.16 Mn |
| Sep 30, 2023 | 13.64 Mn |
| Jun 30, 2023 | 10.41 Mn |
| Mar 31, 2023 | 8.71 Mn |
API Access
Kyverna Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=KYTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "KYTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=KYTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();